

June 18, 2007



The **BANK**
of **NEW YORK**

**A SECURITIES SERVICING
DEPOSITARY RECEIPTS**

Corporate Action

ATTENTION: International Research, Sales, Trading and Operations Staff

Ratio Change & Par Value

| | OLD | NEW |
|--------------------------|---|---|
| Name: | Fresenius Medical Care AG & Co., KGaA (Common) | Fresenius Medical Care AG & Co., KGaA (Common) |
| Country: | Germany | Germany |
| Symbol: | FMS | FMS |
| CUSIP Number: | 358029106 | 358029106 |
| Exchange: | NYSE | NYSE |
| Ratio: | 3 ADRs : 1 ORD | 1 ADR : 1 ORD |

The Bank of New York, as Depositary, has been advised by Fresenius Medical Care AG & Co. KGaA ("FMC") that the German Commercial Registry today approved a 3 for 1 share split in Germany.

As the result of the share split, effective June 18, 2007, the par value of the ordinary shares underlying the FMC ordinary American Depositary Shares ("ADSs") will change to EUR 1.00.

In addition, while the current ADS to ORD ratio is 3 ADSs: 1 ORD, effective June 18, 2007 the ratio will be 1 ADS : 1 ORD. The CUSIP will remain the same. Certificates already held by registered holders will not be called in but will assume the new ratio. No action will be necessary on the part of ADR holders.

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Jason A. Smith
Assistant Treasurer
jasmith@bankofny.com
212 815 3874 Telephone

London

Joseph Oakenfold
Assistant Vice President
joakenfold@bankofny.com
44 207 964 6419 Telephone

This information and data is provided for general informational purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. The Bank of New York does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market value loss on the sale or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. **Please also see "Terms of Use."**